| Literature DB >> 33107490 |
Newton Banupriya1, Ballambattu Vishnu Bhat1, Vinayagam Vickneshwaran2, Magadi Gopalakrishna Sridhar2.
Abstract
Background & objectives: Zinc alters gene expression mainly by binding to a site on the transcription factor. Genome-wide expression studies have shown early repression of genes related to zinc and immunity in adult patients with sepsis. The present study was conducted to evaluate the role of zinc supplementation on relative expression of immune response genes in neonatal sepsis.Entities:
Keywords: Calprotectin; fold change; gene expression; immune response genes; neonatal sepsis; zinc supplementation
Mesh:
Substances:
Year: 2020 PMID: 33107490 PMCID: PMC7881824 DOI: 10.4103/ijmr.IJMR_557_18
Source DB: PubMed Journal: Indian J Med Res ISSN: 0971-5916 Impact factor: 2.375
FigureStudy flow chart.
Demographic characteristics of zinc and control groups
| Characteristics | Control group (n=22) | Zinc group (n=22) |
|---|---|---|
| Male, n (%) | 19 (86.4) | 17 (77.3) |
| Preterm, n (%) | 19 (86.4) | 15 (68.2) |
| Birth weight (kg), mean±SD | 1.72±0.3 | 1.85±0.6 |
| Apgar score at five minutes, median (range) | 8 (6-9) | 8 (6-9) |
| Blood culture positive, n (%) | 6 (27.3) | 7 (31.8) |
| Serum zinc levels (µg/l), mean±SD | ||
| Baseline | 794.7±189.22 | 811.2±129.9 |
| 10th day of supplementation | 824.9±155.2 | 901.15±146.85*** |
***P<0.001 compared to baseline
mRNA expression levels of immune response genes
| Genes | Control group (n=22) | Zinc group (n=22) | Adjusted mean difference (baseline) 95% CI | |||
|---|---|---|---|---|---|---|
| Mean±SD | ||||||
| Baseline | 10th day | Baseline | 10th day | |||
| 2.89±0.83 | 4.89±0.81 | 2.79±0.82 | 3.32±0.82 | 1.58 (1.08-2.08) | <0.001 | |
| 3.53±1.09 | 1.41±0.93 | 4.34±0.89 | 1.71±0.86 | 0.15 (0.74-0.43) | 0.59 | |
| 4.25±1.46 | 4.63±1.28 | 4.51±1.88 | 4.37±1.81 | 0.30 (0.65-1.26) | 0.52 | |
| 3.97±1.15 | 4.32±1.37 | 4.38±1.42 | 4.85±1.18 | 0.58 (1.37-0.20) | 0.14 | |
| 4.11±1.13 | 5.97±1.23 | 4.39±1.38 | 5.78±1.17 | 0.31 (0.33-0.96) | 0.33 | |
| 4.77±1.21 | 6.25±1.14 | 4.45±1.34 | 5.99±1.06 | 0.21 (0.46-0.88) | 0.52 | |
| 4.95±1.58 | 5.68±0.96 | 4.86±1.53 | 6.52±0.97 | 0.86 (1.39-0.33) | 0.002 | |
Fold change of the immune response genes
| Immune response genes | Median (Q1, Q3) | ||
|---|---|---|---|
| Control group (n=22) | Zinc group (n=22) | ||
| Fold change | |||
| 4.69 (2.36, 7.14) | 1.86 (0.57, 3.43) | 0.001 | |
| 1.61 (0.73, 3.59) | 3.38 (2.0, 5.25) | 0.026 | |
| 1.89 (0.45, 3.95) | 1.14 (0.45, 3.21) | 0.62 | |
| 1.50 (0.51, 4.07) | 1.39 (0.88, 4.17) | 0.81 | |
| 5.62 (1.67, 7.69) | 3.42 (1.21, 5.19) | 0.12 | |
| 1.23 (0.71, 3.90) | 3.50 (1.87, 5.56) | 0.03 | |
| 2.90 (1.28, 6.96) | 3.66 (1.30, 5.76) | 0.84 | |
TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; TLR-4, toll-like receptor-4; CD14, cluster of differentiation 14; LBP, lipopolysaccharide binding protein